NCT02786979View on ClinicalTrials.gov

Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Beraprost

Oral

DRUG

Aspirin

Oral

Trial Locations (6)

Unknown

Site CN00001, Beijing

Site CN00002, Beijing

Site CN00004, Guangzhou

Site CN00003, Shanghai

Site CN00005, Chengdu

Site CN00006, Tianjin

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT02786979 - Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients | Biotech Hunter | Biotech Hunter